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gonococcal infections, the added expense of culture and
susceptibility testing.
The study emphasises the importance of determining the
location (chromosomal or plasmid) of antibiotic resistance
genes and the need to characterise these genes individually.
Numerous genetic techniques are available to subtype
bacterial species. The cost-effectiveness of each method
and its relevance need to be established before such
techniques are used in epidemiological studies. By applying
genetic techniques, resistance genes can be characterised,
origins of new resistance determinants can be identified
and, hopefully, dissemination can be contained.
This study was supported by grants to L. J. Chalkley from the
South African Medical Research Council.
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CLINICAL GUIDELINES
Chronic fatigue syndrome
Committee for Science and Education, Medical
Association of South Africa
Objective. To acknowledge the dinical syndrome chronic
fatigue syndrome (CFS) and outline the diagnostic criteria
and reasonable management.
Outcomes. Attempt at containment of treatmentcost
and improvement of the quality of care of patients with
CFS.
Evidence. Delphi-type commentary from 20 expert
clinicians and appropriate organisations. Umiteq literature
survey. ,-
Values. To clarify the reasonable management of CFS
amid conflicting clinical opinion on a condition qf concern
to patients, funders and doctors, An adaptation:of an
existing guideline was sent to organisations and
individuals for comment. Comments received were
included in this guideline where possible.
Benefits, harms and costs. To acknowledge a clinical
syndrome with a reasonable approach to management
considering the cost implications. No cost analysis was
done.
Recommendations. To recommend the following:
(I) diagnostic criteria for CFS; (il) potential differential
diagnoses and possible investigations; and
(iil) management protocol.
Validation. The draft guidelines were subjected to
external review by individual doctors who are
acknowledged CFS treaters, doctor groups and the patient
support group. There were major disputes about the
content, with the responses falling into two groups: those
who do not believe CFS is a distinguishable illness, and
those who do.
Developer and funding. The Committee for Science and
Education, Medical Association of South Africa,
Endorsements. Medical Association of South Africa and
national health care organisations (see list at the end of
the document).
S Atr Med J 1995; 85: 780-782.
Synonyms
Major controversy surrounds the name of the syndrome.
In medical circles the preferred term is chronic fatigue
Committee Members: E. M. Barker (Chairperson), B, M. de Bruijn,
E. J, Immelman, D. G. C. Presbury, A. D. P. v<;In den Berg, D. A. Green,
V. J. Pinkney-Atkinson




syndrome (CFS). Myalgic encephalomyelitis (ME) is a
synonym used extensively outside South Africa, and the
patient support group, the ME Association, has expressed
the wish that the illness should be known as ME. The
syndrome is also called yuppie 'flu.
Objective
To acknowledge the clinical syndrome CFS, and outline the
diagnostic criteria and rational management.
Rationale
In 1993 the Committee for Science and Education of the
Medical Association of South Africa considered the issues
surrounding CFS and published a therapeutic guideline. t
In the light of the MASA clinical guidelines initiative it was
decided to review the guideline and submit it to external
review by concerned groups and individuals. It is clear that
CFS remains controversial and puzzling. While some doctors
continue to deny the existence of CFS as a separate clinical
entity, medical funders are inundated with claims relating to
it. There was a major dispute surrounding the existence of
CFS as a distinguishable illness. The MASA has a continual
stream of enquires from doctors and patients asking for
more information about CFS.
This revised guideline, in meeting the requirements for a
MASA-endorsed guideline, has elicited comment from
doctors, organisations and individuals concerned with the
management of CFS on a daily basis. Their comments have
been incorporated into the successive versions of the
guideline and those who have agreed with the final version
are listed at the end.
The background and history of CFS were documented by
Spracklen.' Many patients and their caregivers are using
complementary therapies, and some use potentially harmful
interventions because CFS has no proven cure. The cost .of
unnecessary investigations and treatment is very high. The
MASA believes that in the absence of adequate research
studies this guideline represents a reasonable approach to
the treatment of CFS.
Methods
The MASA guideline on CFS management was circulated to
a select group of doctors and organisations for comment
and endorsement using a Delphi-type methodology. The
doctors were selected on the basis of knowledge about CFS
and the organisations because their members are involved
with the care of CFS. The ME Association of South Africa
nominated some of the doctor respondents. The draft
guideline was subjected to an extended period of external
review commencing in November 1993 and continuing to
JUly 1994.
Sixteen responses were returned and the comments were
accommodated where possible in the final guideline. The
endorsement list shows only those national or specialist
groups involved with the care of CFS patients on a daily
basis. The MASA funded the guideline project.
Case definition for CFS
The case definition is adapted from that of the Centers for
Disease Control, Atlanta, Georgia.3
A case of CFS must fulfil:
• major criteria 1 and 2
• minor criteria (symptom and/or physical):
either 6 or more of the 11 symptom criteria and 2 or
more of the 3 physical criteria;
or 8 or more of the 11 symptom criteria.
Major criteria
1. New onset of persistent or relapsing, debilitating fatigue
or easy fatiguability in a person with no previous history of
similar symptoms. The fatigue does not resolve with bed
rest. It is severe enough to reduce or impair average daily
activity to below 50% of the patient's premorbid activity
level for a period of at least 6 months.
2. Clinical conditions that should be considered in the
differential diagnosis and must be excluded include:
• malignant disease
• auto-immune disease
• infections (bacterial, fungal, parasitic, viral)
• neuropsychiatric disease
• endocrine disease (e.g. hypothyroidism)
• side-effects of a chronic medication or other toxic agent
(e.g. chemical solvents, pesticides, heavy metals).
Minor criteria
Symptom criteria
To fulfil a symptom criterion, a symptom must have begun
at or after the time of onset of increased fatiguability, and
must have persisted or recurred over a period of at least 6
months (individual symptoms mayor may not have occurred
simultaneously). Symptoms include:
1. Mild fever - oral temperature 37,5 - 38,6°C, if
measured by the patient - or chills. (Note: oral
temperatures about 38,6°C are less compatible with CFS
and should prompt investigations for other causes of
illness.)
2. Sore throat.
3. Painful lymph nodes of anterior or posterior cervical or
axillary distribution.
4. Unexplained generalised muscle weakness.
5. Muscle discomfort or myalgia.
6. Prolonged (24 hours or more) generalised fatigue after
levels of exercise that would have been tolerated easily in
the patient's premorbid state.
"7. Generalised headaches (or a type, severity or pattern
different from headaches in the premorbid state).
8. Migratory arthralgia without joint swelling or redness.
9. One or more of the following neuropsychological
complaints: photophobia, transient visual scotomata,
forgetfulness, excessive irritability, confusion, diffiCUlty in
thinking, inability to concentrate, and depression.
10. Sleep disturbances: hypersomnia or insomnia.
11. Description of the main symptom complex as initially
developing over a few hours to a few days (this is not a true
symptom, but may be considered as equivalent to the above
symptoms in meeting the requirements of the case
definition).
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Physical criteria
These must be documented by a doctor on at least two
occasions at least 1 month apart.
1. Low-grade fever: oral temperature 37,6 - 38,6°C or
rectal temperature 37,8 - 38,8°C. (See note to symptom
criterion 1.)
2. Non-exudative pharyngitis.
3. Palpable or tender anterior or posterior cervical or
axillary lymph nodes. Lymph nodes greater than 2 cm in




Diagnosis rests on clinical findings and appropriate, cost-
effective investigation to exclude other conditions that may
produce similar symptoms. No investigation to establish the
presence of, or previous presence of, any of the viruses
popularly believed to cause the syndrome are of any clinical
value.
Specific laboratory tests or clinical measurements are not
required to satisfy the definition of CFS. The evaluation
suggested below is designed to exclude the conditions
listed in major criteria 2. If the results of any of these tests
are abnormal the doctor should search for other conditions:
• serial weight measurements (weight change more than
10% in the absence of dieting suggests other
diagnoses)
• serial morning and afternoon temperature
measurements
• HIV blood tests: full blood count, ESR, serum urea,
creatinine, sodium, potassium, magnesium, liver
enzymes, rapid plasma reagin and thyroid-stimulating
hormone -
• chest radiographs
• urine tests using dipsticks.
The above investigations should only be pursued when
CFS is reasonably suspected and major criterion 1 and
sufficient minor criteria are met, and not in every tired or
depressed patient.
Management guidelines
The Committee is unaware of any published evidence
supporting the efficacy of the many therapies currently
propagated. At least one publication points out the potential
harm of the therapies.' The high rate of response to placebo
(41 % in one double-blind trial) confounds many of the
anecdotal reports of dramatic improvement in response to
some therapies.s The following guidelines are suggested for
management:
1. Rest. Although the evidence for the efficacy of rest is
anecdotal, it is almost uniformly accepted that it is
beneficial. It should not be seen as a 'cheap' form of
treatment. The cost of absenteeism to the individual and the
employer is potentially substantial.
2. Tricyclic and other antidepressants. Although CFS is
not depression, there is a growing body of anecdotal
evidence that this therapy may be efficacious.
3. Non-steroidal anti-inflammatory drugs may be used to
treat myalgia if indicated.
4. Ufestyle modification including diet, cessation of
smoking and appropriate use of alcohol may be required.
5. Patient support resource. The ME Association of
South Africa (PO Box 461, Hillcrest, 3650) is a patient
support resource to which doctors may wish to refer
patients.
The Committee feels that other forms of treatment should
only take place in the context of an ethically approved
scientific trial. It is acknowledged that other therapies may
become acceptable as knOWledge of CFS grows.
Developed and funded by: MASA Committee for sciEince and
Education.
Groups and organisations endorsing the guideline:
Association of Physicians of South Africa, Chronic Fatigue
Clinic, Cape Town, ME Association of South Africa, Medical
Association of South Africa, National Pathology Groop, South
African Society of Occupational Medicine. ':
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